Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.

Arthritis care & research

Volumn 65, Issue 3, 2013, Pages 362-371

  Weinblatt, Michael E ^a   Kremer, Joel ^b   Cush, John ^b   Rigby, William ^b   Teng, Lichen L ^b   Devenport, Jenny ^b   Singh, Natasha ^b   Lepley, Denise ^b   Genovese, Mark C ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TOCILIZUMAB;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876333416     PISSN: None     EISSN: 21514658     Source Type: None    
DOI: 10.1002/acr.21847     Document Type: Article

References (0)